Analyst Upgrades: eBay Inc, Ionis Pharmaceuticals Inc, and Portola Pharmaceuticals Inc
Analysts upwardly revised their ratings and price targets on eBay Inc (EBAY), Ionis Pharmaceuticals Inc (IONS), and Portola Pharmaceuticals Inc (PTLA)
Analysts upwardly revised their ratings and price targets on eBay Inc (EBAY), Ionis Pharmaceuticals Inc (IONS), and Portola Pharmaceuticals Inc (PTLA)
Analysts are weighing in on internet auction site
eBay Inc (NASDAQ:EBAY), as well as drug stocks
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and
Portola Pharmaceuticals Inc (NASDAQ:PTLA). Here's a quick roundup of today's bullish brokerage notes on EBAY, IONS, and PTLA.
- Baird reiterated its upbeat "outperform" rating on EBAY, as well as its $35 price target -- record-high territory for the shares. That said, the stock has slightly lagged the broader market this year, tacking on roughly 8% in 2016, at $29.79. Plus, as of yet, the shares have failed to close their October post-earnings bear gap. Despite this morning's bullish reiteration, the brokerage community has been largely unimpressed. At present, 15 out of 22 analysts rate eBay Inc a "hold" or worse.
- IONS received price-target hikes from Leerink and Janney -- to $47 and $54, respectively -- after the company's spinal muscular atrophy treatment, developed jointly with Biogen Inc (NASDAQ:BIIB), was approved by the U.S. Food and Drug Administration (FDA). The news has Ionis Pharmaceuticals Inc set to open 6.7% higher, but the shares are sitting on a 13.8% year-to-date deficit, at $53.41. Options traders have been betting against the stock, with IONS holding a 50-day put/call volume ratio of 1.38 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) -- higher than 96% of the past year's readings.
- PTLA is up 0.4% ahead of the bell, after Credit Suisse raised its price target on the stock to $29 from $20, representing a level the shares haven't seen on a closing basis since March. Likely prompting the upbeat note was Friday's news that the FDA granted priority review to the company's blood clot prevention drug, betrixaban -- which helped Portola Pharmaceuticals Inc tack on nearly 34% during the session. But PTLA has had a dismal year so far, shedding over half of its value, at $25.06, and short sellers have been piling on in recent weeks. Specifically, these bearish bets rose by 22.9% during the two most recent reporting periods, and now account for 15.6% of PTLA's available float, or roughly two weeks' worth of buying power, at the stock's typical daily volumes.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check.
Which of These SUB-$5 Stocks Could 26x From Here? (AD)
He called a rare 11x on Tesla…
Then he called a 26x on Workhorse…
Then an even rarer 35x on Nio Inc…
Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.
They’re trading for less than $5 right now.
But thanks to Elon & Trump’s new alliance…
They could be off to the races in Trump’s first 100 days.
And right now for a limited time…
You can get the names & tickers for just $1 here. (AD)